about
Therapeutic interventions in severe asthmaEAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy.Sublingual immunotherapy: World Allergy Organization position paper 2013 update.In chronic idiopathic urticaria autoantibodies against Fc epsilonRII/CD23 induce histamine release via eosinophil activation.A double-blind, placebo-controlled study on the diagnostic accuracy of an electrodermal test in allergic subjects.The perception of Obstructive Sleep Apnoea/Hypopnoea Syndrome (OSAHS) among Italian general practitionersProspective adherence to specific immunotherapy in Europe (PASTE) survey protocol.Choosing wisely: practical considerations on treatment efficacy and safety of asthma in the elderly.Drop-out rate among patients treated with omalizumab for severe asthma: Literature review and real-life experience.360 degree perspective on allergic rhinitis management in Italy: a survey of GPs, pharmacists and patientsAsthma under/misdiagnosis in primary care setting: an observational community-based study in Italy.Research needs in allergy: an EAACI position paper, in collaboration with EFA.Fatal asthma; is it still an epidemic?Asthma control in primary care: the results of an observational cross-sectional study in Italy and Spain.Allergy and the bone: unexpected relationships.The additional values of microarray allergen assay in the management of polysensitized patients with respiratory allergy.Balancing efficacy against safety in sublingual immunotherapy with inhalant allergens: what is the best approach?Safety and tolerability of sublingual immunotherapy in clinical trials and real life.Dropouts in sublingual allergen immunotherapy trials - a systematic review.Potential benefit of omalizumab in respiratory diseases.Omalizumab for severe allergic asthma in clinical trials and real-life studies: what we know and what we should address.Respiratory allergies in childhood: Recent advances and future challenges.Allergic rhinitis: pharmacotherapy in pregnancy and old age.Periostin: The bone and beyond.The clinical characteristics of respiratory allergy in immigrants in northern Italy.Reslizumab and Eosinophilic Asthma: One Step Closer to Precision Medicine?Anaphylaxis and intimate behaviour.Recommendations for assessing patient-reported outcomes and health-related quality of life in patients with urticaria: a GA(2) LEN taskforce position paper.Phenotyping asthma in the elderly: allergic sensitization profile and upper airways comorbidity in patients older than 65 years.Asthma management among allergists in Italy: results from a survey.What lies beyond Asthma Control Test: Suggestions for clinical practice.Clinical efficacy and safety of local nasal immunotherapy.COPD prevalence in a north-eastern Italian general population.SANI-Severe Asthma Network in Italy: a way forward to monitor severe asthma.How much specific is the association between hymenoptera venom allergy and mastocytosis?Omalizumab management beyond clinical trials: the added value of a network model.Sublingual tryptase and ECP in children treated with grass pollen sublingual immunotherapy (SLIT): safety and immunologic implications.Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels.Food-specific IgG4 lack diagnostic value in adult patients with chronic urticaria and other suspected allergy skin symptoms.Wasp venom allergy screening with recombinant allergen testing. Diagnostic performance of rPol d 5 and rVes v 5 for differentiating sensitization to Vespula and Polistes subspecies.
P50
Q28079238-8A41C25B-B65D-46CA-B06B-7A3B2F3B0D7CQ30394524-EAF39E30-39D1-4419-89E9-DE16CCC32FADQ30440195-B261DA58-4CE3-48AF-A7D0-4BD3928B371DQ33230891-4FDCBA4E-663E-4968-B853-F83D1A389F44Q34131626-748BC29D-C3C8-43CA-AA1C-C6B565B4286FQ35424694-D0700106-786B-4025-8C4F-6CFD708DB301Q35540640-F1D19C5A-2A5F-4A67-A9C8-C25A3AAB8FA1Q35765263-BFC79958-1147-4789-BF04-BF3C4D5147ADQ36113704-83DFF118-ED1B-4307-82F1-19BA4175D3F2Q36238142-26357E9C-96B9-4717-ADD3-08EBEEE5D424Q36281473-B69CC305-D09A-4379-B5EF-4FB5AB3366F5Q36517533-01372065-947B-4431-A569-652D1FC488EDQ37501735-EF6BFA28-F8D1-483B-8ADF-D1834AB19FF4Q37739402-8715A44D-B5CB-40B8-A8AF-28B8BD9316D9Q37923545-A538A7DB-56EF-46BE-94AF-26F87A711C34Q38124403-29AB8F6A-D4D5-4EB5-A2E3-86A1543EB4D6Q38149941-F25FB163-41D8-4EFA-8560-CD2962DCFC1EQ38152657-1BD3665D-73C1-434A-9444-C82DF2BEB7FEQ38199748-73099C5E-99C8-47E1-9AAA-BB2B1F225D1AQ38274300-AE474889-AD5A-4930-8D35-38648C554A09Q38339722-4C4A78BB-4D0A-49EF-9F53-2C6487A0F0C6Q38637947-83DB0077-1A53-463E-A994-6F88FBB6B57BQ38833851-42089461-EFDE-400E-ADC4-A9DF1115809CQ39034836-26BF4F8C-CEAE-4F73-B61C-FF1F71047250Q39187901-7EF4B3C8-BA0C-401A-AE3C-FF0984324311Q39201543-5E7FDA02-676A-4BE5-933E-A819ACCA99F4Q39457470-C2100F71-D767-4896-834A-72144840763CQ39774262-2679AE65-CA34-46FC-81C3-2FBC1CA074CCQ40091552-10F88476-B70F-4428-B17D-9E47EAB8CA35Q40201883-EA936FE4-F295-45E6-8832-3F96EDB81495Q40786388-81159E2E-B2AA-45D0-B10E-D3E78BB00BFBQ41503800-54EF8BDD-6FAF-4010-875F-0064F8F2DE13Q41687635-DD37B84B-7D21-4EFB-86C2-215596BF44BDQ42365050-CCED72E8-3254-4C26-A4B0-E9A29333F2ECQ42457384-4D8B0FB0-2ABF-46A9-8484-2D3FEC60E2D4Q42642187-BDBBFCC0-6300-4517-8878-6570869858D6Q43795644-351C6936-D056-480B-A06C-DC8383A9BE2CQ43992711-3947AEBD-4C4B-48E4-B633-FDF3B151455AQ44201495-F51F07BA-A1E2-453D-9258-79EBFD9F5207Q46616496-54C0F428-F699-4A10-B257-16398758FA5B
P50
description
researcher, ORCID id # 0000-0003-4172-3216
@en
wetenschapper
@nl
name
Gianenrico Senna
@ast
Gianenrico Senna
@en
Gianenrico Senna
@es
Gianenrico Senna
@nl
type
label
Gianenrico Senna
@ast
Gianenrico Senna
@en
Gianenrico Senna
@es
Gianenrico Senna
@nl
altLabel
G Senna
@en
G Senna
@nl
prefLabel
Gianenrico Senna
@ast
Gianenrico Senna
@en
Gianenrico Senna
@es
Gianenrico Senna
@nl
P106
P1153
35461418500
P31
P496
0000-0003-4172-3216